Nothing said here yet.
to join the conversation.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026.
Evotec’s latest announcement landed hard. Management cut its 2026 revenue and EBITDA guidance after partnership milestones slipped, then reported weaker Q2 2026 figures with a deeper net loss.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026.
Investing.com -- Evotec shares jumped about 7% in Frankfurt trading after the German drug discovery company said preliminary nine-month results topped market expectations. It also reaffirmed its full-year 2026 guidance.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026.
Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept.
AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept.
Automation, robotics, AI, cloud platforms and RFID are transforming compound management, creating opportunities in drug discovery, biotech, materials science and distributed research.Dublin, Sept.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S.
Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors.